GPC3 and neoplasm: Another macrophage-targeted in vivo therapy against GPC3 using mRNA/LNP technology developed by Carisma Therapeutics and Moderna has also demonstrated a similar favorable preclinical profile with potent dose-dependent cytotoxicity against GPC3+ tumor cells [133] (Table 2).